Veroclast
Instructions for use:
- 1. Release form and composition
- 2. Indications for use
- 3. Contraindications
- 4. Method of application and dosage
- 5. Side effects
- 6. Special instructions
- 7. Drug interactions
- 8. Analogs
- 9. Terms and conditions of storage
- 10. Terms of dispensing from pharmacies
Prices in online pharmacies:
from 3654 rub.
Buy
Veroclast is a drug that inhibits bone resorption in bone metastases.
Release form and composition
Veroclast is available in the following forms:
- concentrate for the preparation of solution for infusion (5 ml in plastic bottles, in a cardboard box 1 bottle or in cardboard boxes of 50 or 80 bottles);
- lyophilisate for preparation of solution for infusion (4 mg in dark glass vials, in a cardboard box 1 bottle).
1 bottle of concentrate for solution for infusion contains 4 mg of zoledronic acid.
1 vial with lyophilisate for preparation of solution for infusion contains 4 mg of zoledronic acid.
Indications for use
- myeloma and bone metastases in malignant solid tumors (to reduce the risk of spinal cord compression, pathological fractures, hypercalcemia induced by a malignant tumor, and reduce the need for radiation therapy);
- hypercalcemia induced by malignant neoplasms (serum calcium concentration more than 3 mmol / l or 12 mg / dl).
Contraindications
Absolute:
- severe renal dysfunction (creatinine clearance less than 30 ml / min);
- children and adolescents up to 18 years of age (since the effectiveness and safety of the drug have not been studied);
- period of pregnancy and lactation;
- hypersensitivity to the drug and other bisphosphonates.
Relative (Veroclast is used with caution):
- impaired renal function of mild to moderate severity;
- bronchial asthma in patients sensitive to acetylsalicylic acid.
Method of administration and dosage
Veroclast is injected intravenously for at least 15 minutes.
For hypercalcemia induced by malignant neoplasms (serum calcium concentration more than 3 mmol / L or 12 mg / dL), the maximum recommended dose of the drug is 4 mg.
Before the introduction of Veroclast, it is necessary to check the serum creatinine concentration. With renal failure of mild or moderate severity, no dosage adjustment is required. Infusion is performed provided the patient is adequately hydrated. For this, 0.9% sodium chloride solution is administered before, simultaneously with the infusion or after it. Repeated administration of Veroclast at a dose of 4 mg is indicated when the condition worsens after the achieved therapeutic effect or in case of resistance to the first administration. There should be an interval of at least one week between the first and repeated infusion to adequately assess the effect. Serum creatinine concentration must be determined before each administration of the drug.
For multiple myeloma and bone metastases, the recommended dose for normal renal function is 4 mg every 3-4 weeks. With mild or moderate renal impairment, the dose of Veroclast is reduced depending on creatinine clearance. Before each dose is administered, the serum creatinine concentration is determined. If kidney dysfunction is detected, the administration of the next dose of the drug should be postponed. The following parameters are used to determine renal dysfunction:
- patients with normal baseline creatinine levels - an increase in serum creatinine concentration of 0.5 mg / dl;
- Patients with abnormal baseline creatinine levels - an increase in serum creatinine concentration by 1 mg / dL.
Treatment is resumed only after reaching a level of creatinine concentration within 10% of the initial value.
In addition to therapy with Veroclast, calcium is prescribed by mouth (500 mg per day) and vitamin D by mouth (400 IU per day).
Before the introduction of the drug, it is necessary to prepare a solution for infusion. The contents of one bottle of concentrate are diluted in 100 ml of infusion solution. A 5% dextrose solution or 0.9% sodium chloride solution can be used as a solvent. It is advisable to use the prepared solution immediately after dilution. The prepared infusion solution can be stored at a temperature of + 2… +8 ° C, but not more than 24 hours. Before the introduction, it should be brought to room temperature, keeping it indoors for some time.
Side effects
- digestive system: often - anorexia, vomiting and nausea; infrequently - dyspeptic disorders, dry mouth, abdominal pain, stomatitis, diarrhea or constipation;
- cardiovascular system: infrequently - a pronounced increase in blood pressure; rarely - bradycardia;
- respiratory system: infrequently - cough, shortness of breath;
- hematopoietic system: often - anemia; infrequently - leukopenia, thrombocytopenia; rarely - pancytopenia;
- nervous system: often - headaches; infrequently - impaired taste, anxiety, paresthesia, hyperesthesia, hypesthesia, sleep disorders, dizziness, tremor; rarely - confusion of consciousness;
- sense organs: often - conjunctivitis; infrequently - blurred visual perception; very rarely - episcleritis, uveitis;
- musculoskeletal system: often - muscle and joint pain, generalized pain, bone pain; infrequently - convulsions;
- urinary system: often - impaired renal function; infrequently - hematuria, acute renal failure, proteinuria;
- skin and skin appendages: infrequently - increased sweating, itching, rash;
- laboratory indicators: very often - a decrease in the level of phosphates in the blood; often - a decrease in the level of calcium in the blood, an increase in the concentration of urea and serum creatinine; infrequently - a decrease in the levels of potassium and magnesium in the blood; rarely - increased levels of sodium and potassium in the blood;
- immune system: infrequently - hypersensitivity reactions; rarely - Quincke's edema;
- other reactions: often - flu-like syndrome, fever; infrequently - peripheral edema, weight gain, asthenia, chest pain;
- local reactions: swelling, irritation, infiltration and pain at the injection site.
Bisphosphonates, including zoledronic acid, can cause osteonecrosis of the jaw (several cases have been noted, usually after tooth extraction or other dental intervention).
Very rarely, when using zoledronic acid, the following reactions were observed: a pronounced decrease in blood pressure, which led to circulatory collapse or fainting (more often in patients with risk factors), atrial fibrillation, bronchoconstriction and drowsiness.
special instructions
After the introduction of Veroclast, it is necessary to constantly monitor the concentration of creatinine, phosphorus, calcium and magnesium in serum. In patients with untreated hypercalcemia, kidney function should be monitored especially closely.
Before prescribing bisphosphonates, a complete dental examination and preventive procedures must be performed. Strict oral hygiene is also recommended. During the treatment period, it is advisable to avoid dental operations.
There is no information about the effect of Veroclast on the patient's ability to drive a car and other vehicles and potentially dangerous mechanisms.
Drug interactions
Veroclast is used with caution together with aminoglycosides and drugs that can potentially cause nephrotoxic effects.
Patients with multiple myeloma with simultaneous intravenous administration of bisphosphonates and thalidomide may increase the likelihood of renal dysfunction.
The solution of zoledronic acid must not be mixed with solutions or preparations containing calcium, as well as any other divalent cations. A separate infusion system must be used to administer the drug.
Analogs
The analogues of Veroclast are: Blaztera, Zoleriks, Zometa, Zoledrex, Zoledronat-Teva, Rezorba, Rezoscan, Rezoklastin FS.
Terms and conditions of storage
Store at a temperature not exceeding 30 ° C. Keep out of the reach of children. Shelf life is 2 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Veroclast: prices in online pharmacies
|
Drug name Price Pharmacy |
|
Veroclast 4 mg lyophilisate for preparation of solution for infusion 1 pc. 3654 RUB Buy |
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
